TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, today announced the successful development of "HPM-L111", the world's first metal*1 palladium (Pd) hydrogen permeable membrane capable of delivering high hydrogen permeation performance at low temperature range around 100C.
More info..

More info..

Honda Motor Co., Ltd. (Honda) today announced plans to begin sales of two U.S.-built models in the Japanese market - the Acura* Integra Type S and Honda Passport TrailSport Elite - in the second half of 2026.
More info..

NTT DOCOMO, INC. announced today that it has developed a new system powered by FEEL TECH(TM) haptic technology that allows fans to experience physical sensations transmitted from artists, creating a stronger sense of closeness with their idols.
More info..

富士通Japan株式会社（注1）（以下、富士通Japan）は、大分県大分市様の公共図書館（以下、大分市民図書館）において、デジタル庁が提供する「デジタル認証アプリ」を活用した図書館のWeb利用者登録サービスを構築し、2026年3月10日に大分市民図書館で運用を開始します。
More info..

Hondaは、米国で生産するAcura※ブランドの「ACURA INTEGRA Type S（アキュラ インテグラ タイプエス）」とHondaブランドの「PASSPORT TRAILSPORT ELITE（パスポート トレイルスポーツ エリート）」の2モデルを日本市場に導入し、2026年後半より順次発売します。
More info..

Core Concepts Physio, one of Singapore's leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain.
More info..

FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium - a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework.
More info..

ロンドンを拠点とするBase58 Labsは、極めて戦略的な3,500万ドルのPre-Series A資金調達を完了し、同社の主力暗号資産ステーキングプラットフォームである「BASIS」の開発を大幅に加速させています。
More info..

More info..

三菱重工業株式会社 取締役社長 CEO 伊藤 栄作は、このほどグローバルビジネス誌Forbes JAPANが選定する「CIO AWARD 2025-2026」でグランプリに選ばれました。
More info..

TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, today announced a gold bump*1 transfer technology for the sintered gold (Au) bonding technology, AuRoFUSE(TM) Preforms.
More info..

Fujitsu and BCN Port Innovation Foundation today announced a new agreement between Fujitsu Spain and the BCN Port Innovation Foundation to develop a proof of concept (PoC) for an ocean digital twin at the Port of Barcelona.
More info..

Mitsubishi Heavy Industries, Ltd. (MHI) and SoftBank Corp. (SoftBank) today announced the launch of a demonstration experiment using SoftBank's AI-RAN product "AITRAS" to deploy edge AI applications within the edge data center "DIAVAULT" solution installed at MHI's Yokohama Hardtech Hub (YHH).
More info..

三菱重工業株式会社（以下、三菱重工）とソフトバンク株式会社（以下、ソフトバンク）は、当社横浜製作所（横浜市中区）のYokohama Hardtech Hub（YHH）に設置されたエッジデータセンター（注1）「DIAVAULT（ディアヴォルト）」において、ソフトバンクのAI-RANプロダクト（注2）「AITRAS（アイトラス）」を活用したエッジAIアプリケーション（注3）の実証実験を実施します。
More info..

More info..

NTT DOCOMO, INC. and NEC Corporation today announced the launch of Japan's first commercial 5G core network (5GC) on Amazon Web Services (AWS) on February 26.
More info..

Fujitsu Limited today announced the launch of Uvance for Retail, a solution that integrates data onto a robust and secure cloud. The solution, which leverages Fujitsu's accumulated business knowledge and implementation capabilities, also incorporates advanced technologies such as agentic AI.
More info..

Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG(R) (belzutifan), Merck & Co., Inc., Rahway, NJ, USA's first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor, plus LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy.
More info..